替考拉宁治疗药物监测临床实践指南:日本化学疗法学会与日本治疗药物监测学会共识综述
日本化学疗法学会与日本治疗药物监测学会联合制定替考拉宁TDM指南,系统评价并Meta分析显示目标谷浓度15-30 mg/L较<15 mg/L提高非复杂性MRSA感染疗效(OR=2.68;95%CI=1.14-6.32),且未增加不良反应;复杂性或严重感染建议20-40 mg/L(证据不足)。
要点
- 非复杂性MRSA感染目标谷浓度15-30 mg/L,较<15 mg/L临床疗效提高(OR=2.68;95%CI=1.14-6.32),未增加不良反应。
- 复杂性或严重MRSA感染建议目标谷浓度20-40 mg/L(证据不足)。
- 推荐3天负荷方案后按肾功能维持给药,并在第4天稳态前测谷浓度。
核心结论
- 新指南推荐了替考拉宁TDM的目标谷浓度值及达到该浓度的给药方案,并针对特定亚群提出实践建议。
研究设计与样本
- 由委员会按照日本医疗信息服务发布的方理手册制定指南,选取9个临床问题,进行系统评价与Meta分析以确定目标谷浓度的循证推荐。
- 初步电子数据库检索返回515篇文章,97篇符合全文审查条件;分别有4项和5项研究纳入15 mg/L和20 mg/L谷浓度界值的疗效评价。
主要发现
- 与非复杂性MRSA感染患者谷浓度<15 mg/L相比,目标谷浓度15-30 mg/L使临床疗效提高(OR=2.68;95%CI=1.14-6.32),且未增加不良反应。
- 尽管证据不足,复杂性或严重MRSA感染患者建议目标谷浓度20-40 mg/L。
关键数值与推荐
- 非复杂性MRSA感染:目标谷浓度15-30 mg/L,较<15 mg/L临床疗效提高(OR=2.68;95%CI=1.14-6.32),未增加不良反应。
- 复杂性或严重MRSA感染:建议目标谷浓度20-40 mg/L(证据不足)。
- 推荐3天负荷方案后按肾功能进行维持治疗,以达到目标谷浓度。
- 因替考拉宁半衰期延长,推荐在第4天尚未达稳态时测定谷浓度。
临床怎么用
- 对接受替考拉宁治疗的MRSA感染患者应开展TDM,非复杂性感染目标谷浓度15-30 mg/L,复杂性或严重感染建议20-40 mg/L。
- 采用3天负荷方案后按肾功能维持给药,并在第4天稳态前测定谷浓度以评估是否达标。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Owing to its low risk of adverse effects, teicoplanin has been extensively used in patients with infections caused by MRSA. To promote the better management of patients receiving teicoplanin, we have updated the guidelines for therapeutic drug monitoring (TDM). METHODS: The guidelines were developed by a committee following the methodology handbook published by the Japanese Medical Information Distribution Service. Nine clinical questions were selected. The committee conducted a systematic review and meta-analysis to establish evidence-based recommendations for the target trough concentration (Cmin). An initial electronic database search returned 515 articles, and 97 articles qualified for a full review. Four and five studies were included for the efficacy evaluation of cut-off Cmin values of 15 and 20 mg/L, respectively. RESULTS: Compared with Cmin < 15 mg/L, a target Cmin value of 15-30 mg/L resulted in increased clinical efficacy in patients with non-complicated MRSA infections (OR = 2.68; 95% CI = 1.14-6.32) without an increase in adverse effects. Although there was insufficient evidence, target Cmin values of 20-40 mg/L were suggested in patients with complicated or serious MRSA infections. A 3 day loading regimen followed by maintenance treatment according to renal function was recommended to achieve the target trough concentrations. Because of the prolonged half-life of teicoplanin, measurement of the Cmin value on Day 4 before reaching steady state was recommended. CONCLUSIONS: The new guideline recommendations indicate the target Cmin value for TDM and the dosage regimen to achieve this concentration and suggest practices for specific subpopulations.
引用
- Hanai Y, Takahashi Y, Niwa T, et al. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Antimicrob Chemother. 2022. PMID: 35022752. doi:10.1093/jac/dkab499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。